Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies-Reference-Cited by-同舟云学术

Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies

Published:2021-08-31 Issue:2 Volume:88 Page:551-565
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Stanulović Vid¹^ORCID,Hodolic Marina²³,Mitsikostas Dimos D.⁴,Papadopoulos Dimitrios⁵

Affiliation:

1. Global Pharmacovigilance, R&D Sanofi Chilly‐Mazarin France

2. Nuclear Medicine Research Department IASON Graz Austria

3. Department of Nuclear Medicine, Faculty of Medicine and Dentistry Palacký University Olomouc Czech Republic

4. 1st Neurology Department, Aeginition Hospital, Medical School National and Kapodistrian University of Athens Athens Greece

5. School of Medicine European University Cyprus Athens Greece

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15016

Reference45 articles.

1. Risk stratification and mitigation multiple sclerosis;Ontaneda D;Mult Scler Relat Disord,2014

2. Factors that influence adherence with disease‐modifying therapy in MS;Treadaway K;J Neurol,2009

3. Anti‐CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis;Drellia K;Cephalalgia,2021

4. CGRP‐antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: a systematic review and meta‐analysis;Frank F;Cephalalgia,2021

5. Nausea and vomiting associated with selective serotonin reuptake inhibitors;McManis PG;CNS Drugs,1997

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Efficacy and Metabolomics Modifications Induced by Polyphenol Compound Supplementation in the Treatment of Residual Dizziness following Semont Maneuver in Benign Paroxysmal Positional Vertigo (BPPV) of the Posterior Semicircular Canal (PSC): Preliminary Results;Metabolites;2024-01-25

2. Using Denosumab as a Nonsurgical Management of Aneurysmal Bone Cysts in the Pelvis;Clinics in Orthopedic Surgery;2024

3. Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag;Journal of Patient-Reported Outcomes;2023-12-18

4. Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis;Headache: The Journal of Head and Face Pain;2023-11

5. A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events;British Journal of Cancer;2023-07-07